RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Activating Invasion and Metastasis in Small Cell Lung Cancer: Role of the Tumour Immune Microenvironment and Mechanisms of Vasculogenesis, Epithelial-Mesenchymal Transition, Cell Migration, and Organ Tropism.
Activating Invasion and Metastasis in Small Cell Lung Cancer: Role of the Tumour Immune Microenvironment and Mechanisms of Vasculogenesis, Epithelial-Mesenchymal Transition, Cell Migration, and Organ Tropism.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
SCLC 的治疗因其顽固和侵袭性的特点仍然是一个临床挑战。在 SCLC 用以实现其侵袭性行为的众多标志中,其侵入周围组织和转移的能力尤为显著,理解 SCLC 转移的分子机制可以识别治疗靶点,以减弱 SCLC 的侵袭性并改善死亡率。
小细胞肺癌(SCLC)在所有肺癌中具有最具侵袭性的表型,与其黯淡的预后相关。SCLC的侵袭性部分归因于其强烈的转移倾向。促进SCLC转移的生物学过程仍知之甚少,更深入地理解这些过程可能有助于探索针对这一癌症标志的额外靶点,用于SCLC的治疗。
本叙述性综述将讨论所提出的分子机制,即激活侵袭和转移这一癌症标志如何通过转移通路的重要步骤在 SCLC 中体现,并探讨可考虑用于治疗干预的各种分子靶点。肿瘤免疫微环境在促进免疫治疗耐药方面发挥重要作用,而NK 细胞浸润不良尤其促成了 SCLC 中的促转移环境。SCLC 的血管生成通过 VEGF 表达和血管拟态实现,而上皮-间质转化则由 E-cadherin 转录抑制因子的表达、Notch 信号通路的抑制和肿瘤异质性所促进。核因子 I/B、选择素和 B1 整合素在 SCLC 迁移中发挥重要作用,而 SCLC 表达多种分子标志物以协助转移过程中的器官特异性归巢。本综述还将讨论一篇近期文章,该文章观察到 miR-1 mRNA 上调作为靶向 SCLC 转移活性的潜在治疗选择。
Small cell lung cancer (SCLC) harbours the most aggressive phenotype of all lung cancers to correlate with its bleak prognosis. The aggression of SCLC is partially attributable to its strong metastatic tendencies. The biological processes facilitating the metastasis in SCLC are still poorly understood and garnering a deeper understanding of these processes may enable the exploration of additional targets against this cancer hallmark in the treatment of SCLC. RECENT FINDINGS: This narrative review will discuss the proposed molecular mechanisms by which the cancer hallmark of activating invasion and metastasis is featured in SCLC through important steps of the metastatic pathway, and address the various molecular targets that may be considered for therapeutic intervention. The tumour immune microenvironment plays an important role in facilitating immunotherapy resistance, whilst the poor infiltration of natural killer cells in particular fosters a pro-metastatic environment in SCLC. SCLC vasculogenesis is achieved through VEGF expression and vascular mimicry, and epithelial-mesenchymal transition is facilitated by the expression of the transcriptional repressors of E-cadherin, the suppression of the Notch signalling pathway and tumour heterogeneity. Nuclear factor I/B, selectin and B1 integrin hold important roles in SCLC migration, whilst various molecular markers are expressed by SCLC to assist organ-specific homing during metastasis. The review will also discuss a recent article observing miR-1 mRNA upregulation as a potential therapeutic option in targeting the metastatic activity of SCLC.
Treatment of SCLC remains a clinical challenge due to its recalcitrant and aggressive nature. Amongst the many hallmarks used by SCLC to enable its aggressive behaviour, that of its ability to invade surrounding tissue and metastasise is particularly notable and understanding the molecular mechanisms in SCLC metastasis can identify therapeutic targets to attenuate SCLC aggression and improve mortality.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。